scholarly article | Q13442814 |
P819 | ADS bibcode | 2013PLoSO...874253X |
P356 | DOI | 10.1371/JOURNAL.PONE.0074253 |
P932 | PMC publication ID | 3753304 |
P698 | PubMed publication ID | 23991216 |
P5875 | ResearchGate publication ID | 256292109 |
P50 | author | Jie Ni | Q38523771 |
Weiwei Xiao | Q64927805 | ||
P2093 | author name string | Yong Li | |
John H Kearsley | |||
Lei Chang | |||
Qihan Dong | |||
Peter H Graham | |||
Carl A Power | |||
Jingli Hao | |||
P2860 | cites work | Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair | Q26863429 |
Pathways governing G1/S transition and their response to DNA damage | Q28202348 | ||
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis | Q28277806 | ||
Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer | Q33256354 | ||
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression | Q33482138 | ||
Sensing and repairing DNA double-strand breaks | Q34642563 | ||
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein | Q34742793 | ||
Role of cell cycle in mediating sensitivity to radiotherapy | Q35826593 | ||
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. | Q35864090 | ||
Postradiation sensitization of the histone deacetylase inhibitor valproic acid | Q36085669 | ||
DNA-damage repair; the good, the bad, and the ugly | Q36487307 | ||
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects | Q36617012 | ||
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents | Q36645808 | ||
Histone deacetylase inhibitors: signalling towards p21cip1/waf1. | Q36782509 | ||
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis | Q36849135 | ||
Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero | Q37086523 | ||
P53, cyclin-dependent kinase and abnormal amplification of centrosomes | Q37109906 | ||
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors | Q37440094 | ||
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors | Q37515346 | ||
Developing histone deacetylase inhibitors as anti-cancer therapeutics | Q37856325 | ||
Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy | Q37998519 | ||
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers | Q38095611 | ||
Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer | Q39313134 | ||
Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells | Q39580891 | ||
Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer | Q39632081 | ||
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression | Q39663662 | ||
Attenuated DNA damage repair by trichostatin A through BRCA1 suppression | Q40088892 | ||
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci | Q40240295 | ||
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen | Q40545805 | ||
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. | Q43136243 | ||
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. | Q46905304 | ||
How low is the α/β ratio for prostate cancer? | Q47426446 | ||
Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiation-induced breakpoints | Q73681450 | ||
Histone deacetylase inhibitors | Q80489191 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P4510 | describes a project that uses | ImageQuant | Q112270642 |
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adaptive radiation therapy | Q180507 |
prostate cancer | Q181257 | ||
P304 | page(s) | e74253 | |
P577 | publication date | 2013-08-26 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells | |
P478 | volume | 8 |
Q38911199 | Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers |
Q89078193 | CD44 collaborates with ERBB2 mediate radiation resistance via p38 phosphorylation and DNA homologous recombination pathway in prostate cancer |
Q26771165 | Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization |
Q52590685 | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. |
Q53749396 | Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. |
Q28071912 | Epigenetic modulators as therapeutic targets in prostate cancer |
Q53575196 | HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. |
Q35006481 | Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells |
Q38844402 | Knockdown of Rad9A enhanced DNA damage induced by trichostatin A in esophageal cancer cells |
Q35691776 | Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells |
Q38951260 | PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways |
Q37687556 | Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. |
Q46038047 | Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. |
Q38848047 | Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells |
Q50926267 | Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. |
Q36810416 | The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines. |
Search more.